Headquartered in Toronto, ON, Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept, and Phase I to IV studies in allergy, asthma, ocular studies and dermatology. Inflamax has unique electronic data collection tools for single and multi-center EEC and field studies which greatly improve the quality and speed of data collection in clinical trials. In addition to the Next Generation Mobile EECs, Inflamax has two Next Generation EECs fixed in place at Inflamax headquarters in Toronto, ON. These EECs are already validated for Ragweed, Grass and Dry Eye (low humidity). Validations are currently in process for cat and dust mite allergens.
About Dr Patel
Dr. Piyush Patel, Inflamax’s CEO is an industry veteran who has been in the forefront of development in EEC technology. Dr. Patel is an author of several patents relating to EEC technology and has been involved in the development of many mainstay anti-allergy drugs and immunotherapies currently on the market. He was the owner of Allied Research International; a CRO specializing in EECs, which was sold in 2007. Dr. Patel was also named Entrepreneur of the Year in 2008 for his work in building that company.
Read the full story at http://www.prweb.com/releases/2013/1/prweb10325385.htm.
Copyright©2012 Vocus, Inc.
All rights reserved